Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pathway to Cures (P2C) is the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), established to accelerate the development of cures and therapies for inheritable blood and bleeding disorders. Founded to address the critical funding gap in early-stage therapy development, P2C operates independently while leveraging the resources and expertise of NBDF. The organization is based in New York City and focuses on innovative therapeutic approaches in the biotech and healthcare sectors.
Currently, P2C targets early-stage funding opportunities, specifically in the pre-seed, seed, and seed-plus stages. The organization aims to attract additional capital from traditional venture capital, biotech, and pharmaceutical entities. While specific metrics such as fund size or portfolio count are not disclosed, P2C's strategic investments cover a range of innovative therapies for various inheritable blood disorders, demonstrating a commitment to advancing medical research and treatment options.
P2C invests in companies that have the potential to develop innovative therapies and technologies for inheritable blood and bleeding disorders. Their investment strategy emphasizes early-stage funding opportunities, particularly in the pre-seed, seed, and seed-plus stages. The organization focuses on various therapeutic approaches, including RNA technology, engineered B-cells, and non-invasive medical devices.
Pathway to Cures seeks to address the funding gap in early-stage development by investing in companies that target conditions such as Hemophilia, Sickle Cell Disease, and Von Willebrand Disease. Their approach includes attracting additional capital from traditional venture capital and pharmaceutical entities, enhancing the potential for groundbreaking therapies. P2C's commitment to innovative solutions positions them as a key player in the biotech and healthcare sectors.
P2C's portfolio includes investments in several strategic areas aimed at addressing inheritable blood disorders:
These investments reflect P2C's commitment to advancing innovative therapies that address significant medical needs in the field of blood disorders.
Teri Willey, Managing Director & Officer, has extensive experience in venture philanthropy and healthcare investments.
Michael Recht, MD, PhD, MBA, Chair of the Scientific Advisory Group and Chief Medical and Scientific Advisor, brings a strong medical background and expertise in blood disorders.
Tim Brent, MBA, Venture Principal, has a background in venture capital and strategic investments in healthcare.
Leonard Valentino, MD, Entrepreneur in Residence, is known for his work in clinical research and development in the biotech sector.
Peter Harvey, MBA, Chief Financial Officer and Chief Business Officer of NBDF, oversees financial operations and strategic partnerships.
Beth Whitehouse, Senior Vice President for Advancement at NBDF, focuses on fundraising and community engagement initiatives.
To pitch to Pathway to Cures, startups should email info@pathwaytocures.org with a detailed pitch deck. The deck should include information about the business model, therapeutic approach, market potential, and team expertise. P2C values clear communication and a well-defined strategy.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory.
Recently, Pathway to Cures announced partnerships and updates, including the launch of Spark Biomedical’s LUNA Trial aimed at non-pharmaceutical options for heavy menstrual bleeding. This initiative reflects P2C's commitment to exploring innovative treatment options.
Additionally, P2C has published insights on building better therapies through patient panels, emphasizing their engagement with the community. They have also shared updates on their annual fund, highlighting their ongoing efforts to advance research in inheritable blood disorders.
What are Pathway to Cures' investment criteria?
P2C invests in early-stage companies developing innovative therapies and technologies for inheritable blood and bleeding disorders. They focus on sectors such as biotech and healthcare, particularly targeting pre-seed, seed, and seed-plus stages.
How can startups apply or pitch to Pathway to Cures?
Startups can reach out via email at info@pathwaytocures.org to discuss potential investment opportunities. A detailed pitch deck outlining the business model, therapeutic approach, and market potential is recommended.
What makes Pathway to Cures different from other investors?
P2C operates as a venture philanthropy fund, leveraging the resources of the National Bleeding Disorders Foundation to address funding gaps in early-stage therapy development. Their focus on inheritable blood disorders sets them apart in the investment landscape.
What is the geographic scope of Pathway to Cures' investments?
P2C primarily invests in North America, targeting companies that are innovating in the biotech and healthcare sectors.
What is Pathway to Cures' involvement post-investment?
P2C engages with portfolio companies to provide support and resources, facilitating connections with traditional venture capital and pharmaceutical entities to enhance development opportunities.
What is the typical check size for investments made by Pathway to Cures?
While specific check sizes are not disclosed, P2C focuses on early-stage funding, which typically involves smaller investments aimed at supporting initial development phases.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.